Skip to main content
SpringerLink
Log in

Therapie mit Thrombozyten

  • Chapter
Transfusionsmedizin

  • 244 Accesses

Zusammenfassung

Dank der heute in fast allen Fällen möglichen supportiven Therapie mit Thrombozyten ist der Bedarf an Thrombozytenkonzentraten im letzten Jahrzehnt in den medizinisch entwickelten Ländern stark angestiegen. Ihre medizinische Bedeutung kommt inzwischen der von Erythrozytenkonzentraten nahe. In Deutschland werden derzeit mehr als 500000 Thrombozytentransfusionen jährlich durchgeführt. Die in das thrombozyten-stimulierende Hormon Thrombopoietin gesetzten Erwartungen haben sich nicht erfüllt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andreu G, Dewailly J (1994) Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hem Blood Transfus 60: 29–40

    Google Scholar 

  2. Anonymous, Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components (2001) Pathogen inactivation of labile blood products. Transfus Med 11: 149–175

    Article  Google Scholar 

  3. Aster RH (1966) Pooling of platelets in the spleen: role in the pathogenesis of »hypersplenic« thrombocytopenia. J Clin Invest 45: 645–657

    Article  PubMed  CAS  Google Scholar 

  4. Atoyebi W, Mundy N, Croxton T, Littlewood TJ, Murphy MF (2000) Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 111: 980–983

    Article  PubMed  CAS  Google Scholar 

  5. Baer MR, Bloomfield CD (1992) Prophylactic platelet transfusion therapy: Pro. Transfusion 32: 377–380

    Article  PubMed  CAS  Google Scholar 

  6. Benson K, Marks AR, Marshall MJ, Goldstein JD (1994) Fatal graftversus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transfusion 34: 432–437

    Article  PubMed  CAS  Google Scholar 

  7. Beutler E (1993) Artificial preservatives for platelets. Transfusion 33: 279–280

    Article  PubMed  CAS  Google Scholar 

  8. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J (1991) Factors influencing 20-hour increments after platelet transfusion. Transfusion 31: 392–396

    Article  PubMed  CAS  Google Scholar 

  9. Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J (1992) The definition of refractoriness to platelet transfusions. Transfus Med 2: 35–41

    Article  PubMed  CAS  Google Scholar 

  10. Blajchman MA, Goldman M (2001) Bacterial contamination of platelet concentrates: incidence, significance and prevention. Sem Hema 4 Suppl 11: 20–26

    Article  Google Scholar 

  11. Blumberg N, Heal JM, Hicks GL, Risher WH (2001) Association of AB0-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41: 790–793

    Article  PubMed  CAS  Google Scholar 

  12. Böck M, Rahrig S, Kunz D, Lutze G, Heim MU (2002) Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 12: 311–316

    Article  Google Scholar 

  13. Brand A (1994) Passenger leukocytes, cytokines and transfusion reactions. N Engl J Med 331: 670–671

    Article  PubMed  CAS  Google Scholar 

  14. Brand A (2001) Alloimmune platelet refractoriness: incidence declines, unsolved problems persist Transfusion 41: 724–726

    Article  PubMed  CAS  Google Scholar 

  15. Callow CR, Swindell R, Randall W, Chopra R (2002) The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 118(2): 677–682

    Article  PubMed  Google Scholar 

  16. Couban S, Carruthers J, Andreou P et al. (2002) Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 42: 753–758

    Article  PubMed  Google Scholar 

  17. Davis KB, Slichter SJ, Corash L (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39: 586–592

    Article  PubMed  CAS  Google Scholar 

  18. Delaflor-Weiss E, Mintz PD (2000) The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 14: 180–196

    Article  PubMed  CAS  Google Scholar 

  19. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH (1994) Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66: 200–205

    Article  PubMed  CAS  Google Scholar 

  20. Duke WW (1910) The relation of biood platelets to hemorrhagic disease: description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 55: 1185–1192

    Article  Google Scholar 

  21. Dumont U, AuBuchon JP, Whitley P et al. (2002) Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 42: 847–854

    Article  PubMed  Google Scholar 

  22. Ferrara JLM (1995) The febrile platelet transfusion reaction: a cytokine shower. Transfusion 35: 89–90

    Article  PubMed  CAS  Google Scholar 

  23. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S (2002) Do basic laboratory tests or clinical observations predict bleeding in thromobcytopenic patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16: 34–45

    Article  PubMed  Google Scholar 

  24. Gawaz M (1999) Das Blutplättchen. Thieme, Stuttgart New York

    Google Scholar 

  25. Gharpure VS, Norris D, Lee EJ, Schiffer CA (1994) Use of »split« plateletpheresis products for alloimmunized patients. Vox Sang 67: 272–274

    Article  PubMed  CAS  Google Scholar 

  26. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A (1991) Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338: 1223–1226

    Article  PubMed  Google Scholar 

  27. Grishaber JE, Birney SM, Strauss RG (1993) Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Transfusion 33: 910–914

    Article  PubMed  CAS  Google Scholar 

  28. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT (1981) Hazard of platelet transfusion in thrombotic thrombocytopenic pupura. JAMA 246: 1931–1933

    Article  PubMed  CAS  Google Scholar 

  29. Harrison P, Robinson M, Liesner R et al. (2002) The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haem 24: 225–232

    Article  Google Scholar 

  30. Heddle NM, Blajchman MA (1995) The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 85: 603–606

    PubMed  CAS  Google Scholar 

  31. Heddle NM, Blajchman MA, Meyer RM et al. (2002) A randomized, controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42: 556–566

    Article  PubMed  Google Scholar 

  32. Heddle NM, Klama L, Singer J et al. (1994) The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 331: 625–628

    Article  PubMed  CAS  Google Scholar 

  33. Heddle NM, Soutar RL, O’Hoski PL, Singer J, McBride JA, Ali MAM, Kelton JG (1995) A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 91: 1000–1005

    Article  PubMed  CAS  Google Scholar 

  34. Heim MU, Böck M, Kolb H-J, Schleuning M, Mempel W (1992) Intravenous anti-D gammaglobulin for the prevention of Rhesus isoimmunization caused by platelet transfusions in patients with malignant diseases. Vox Sang 62: 165–168

    Article  PubMed  CAS  Google Scholar 

  35. Kickler T, Braine HG, Piantadosi S et al. (1990) A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 75: 313–316

    PubMed  CAS  Google Scholar 

  36. Kiefel V, König C, Kroll H, Santoso S (2001) Platelet alloantibodies in transfused patients. Transfusion 41: 766–770

    Article  PubMed  CAS  Google Scholar 

  37. Klüter H, Salama A (2001) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: Thrombozytenkonzentrate, pp. 27 – 43. Deutscher Ärzteverlag Köln

    Google Scholar 

  38. Kretschmer V, Huss B, Weber S, Bewarder S, Schulzki T, Köppler H, Heimanns J (1994) A contribution to the indications for platelet transfusion and determination of its therapeutic efficacy. Transfus Sci 15: 361–369

    Article  PubMed  CAS  Google Scholar 

  39. Kuter DJ, Goodnough LT, Romo J et al. (2001) Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98: 1339–1345

    Article  PubMed  CAS  Google Scholar 

  40. Li J, Yang Ch, Xia Y et al. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98: 3241–3248

    Article  PubMed  CAS  Google Scholar 

  41. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, Rowe JM, Saleh MN, Arndt P, Foley K, Masel D, Postoway N (1992) Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 32: 633–640

    Article  PubMed  CAS  Google Scholar 

  42. Mueller-Eckhardt C, Scharf R, Greinacher A (1993) Thrombozytäre hämorrhagische Diathesen. In: Begemann H, Rastetter J: Klinische Hämatologie. 4. Aufl. Thieme, Stuttgart New York, S 870 – 944

    Google Scholar 

  43. Murphy MF, Brozovic B, Murphy W, Ouwehand W, Waters AH (1992) Guidelines for platelet transfusions. Transfus Med 2: 311–318

    Article  PubMed  CAS  Google Scholar 

  44. Murphy S (2002) What’s so bad about old platelets? Transfusion 42: 809–811

    Article  PubMed  Google Scholar 

  45. Murphy S, Rebuila P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg R for the BEST Task Force of the ISBT. (1994) In vitro assessement of the quality of stored platelet concentrates. Transfus Med Rev 8: 29–36

    Article  PubMed  CAS  Google Scholar 

  46. Muylle L, Wouters E, de Bock R, Peetermans ME (1992) Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 2: 289–293

    Article  PubMed  CAS  Google Scholar 

  47. Ness P, Braine H, King K, Barrasso C, Kickler T, Fuller A, Blades N (2001) Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 41: 857–861

    Article  PubMed  CAS  Google Scholar 

  48. Ness PM, Campbell-Lee SA (2001) Single donor versus random donor platelet concentrates. Curr Opin Hem, Nov. 8 (6): 392–396

    Article  CAS  Google Scholar 

  49. Novotny VMJ, van Doom R, Witvliet MD, Claas FHJ, Brand A (1995) Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 85: 1736–1741

    PubMed  CAS  Google Scholar 

  50. Panzer S, Kiefel V, Bartram CR, Haas OA, Hinterberger W, Mueller-Eckhardt C, Lechner K (1989) Immune thrombocytopenia more than a year after allogenetic marrow transplantation due to antibodies against donor platelets with anti-PI(A1) specificity: evidence for a host-derived immune reaction. Br J Haematol 71: 259–264

    Article  PubMed  CAS  Google Scholar 

  51. Patten E (1992) Prophylactic platelet transfusion revisited after 25 years: con. Transfusion 32: 381–385

    Article  PubMed  CAS  Google Scholar 

  52. Rebulla P, Finazzi G, Marangoni F et al. (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. New England Journal of Medicine 337: 1870–1875

    Article  PubMed  CAS  Google Scholar 

  53. Reesink HW, Nydegger UE, Brand A et al. (1992) International Forum: Should all platelet concentrates issued be lookocyte-poor? Vox Sang 62: 60–61

    Article  Google Scholar 

  54. Rock GA (1993) The application of protein A immunoadsorption to remove platelet alioantibodies. Transfusion 33: 192–194

    Article  PubMed  CAS  Google Scholar 

  55. Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109: 496–507

    Article  PubMed  CAS  Google Scholar 

  56. Rubia J de la, Plume G, Arriaga F et al. (2002) Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 42: 1384–1385

    Article  PubMed  Google Scholar 

  57. Saarinen UM, Koskimies S, Myllylä G (1993) Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang 65: 286–292

    Article  PubMed  CAS  Google Scholar 

  58. Sagmeister M, Oec L, Gmür J (1999) A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 93: 3124–3126

    PubMed  CAS  Google Scholar 

  59. Sanz C, Freire C, Alcorta I, Ordinas A, Pereira A (2001) Plateletspecific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 41: 762–765

    Article  PubMed  CAS  Google Scholar 

  60. Schiffer CA (2001) Diagnosis and management of refractoriness to platelet transfusion. Blood Reviews 15: 175–180

    Article  PubMed  CAS  Google Scholar 

  61. Schiffer CA, Anderson KC, Bennett CL et al. (2001) Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1519–1538

    PubMed  CAS  Google Scholar 

  62. Schnaidt M, Northoff H, Wernet D (1996) Frequency and specificity of platelet-specific alioantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 6: 111–114

    Article  PubMed  CAS  Google Scholar 

  63. Shivdasani RA, Anderson KC (1993) Transfusion-associated graftversus-host disease: scratching the surface. Transfusion 33: 696 – 697

    Google Scholar 

  64. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WU, Claas FHJ, Novotny VMJ, Brand A (1995) Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 85: 824–828

    PubMed  CAS  Google Scholar 

  65. Skogen B, Rosseby Hansen B, Husebekk A, Havnes T, Hannestad K (1988) Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion 28: 456–459

    Article  PubMed  CAS  Google Scholar 

  66. Slichter SJ (1990) Mechanisms and Management of Platelet Refractoriness. In: Nance SJ (ed) Transfusion Medicine in the 1990’s. American Association of Blood Banks, Arlington, pp. 95 – 179

    Google Scholar 

  67. Söhngen D, Hattstein E, Heyll A, Kuntz BME, Meckenstock G, Schneider W (1994) Ex-vivo-Blutungszeit zur Kontrolle der Thrombozytentransfusion. Beiträge zur infusionstherapie und Transfusionsmedizin 32: 459–466

    PubMed  Google Scholar 

  68. Stefanini M, Dameshek W (1953) Collection, preservation and transfusion of platelets. N Engl J Med 248: 797–802

    Article  PubMed  CAS  Google Scholar 

  69. Taaning E, Jacobsen N, Morling N (1994) Graft-derived anti-HPA- 2 b production after allogeneic bone-marrow transplantation. Br J Haematol 86: 651–653

    Article  PubMed  CAS  Google Scholar 

  70. The Trial to Reduce Alloimmunization to Platelets Study Group (1997) Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337: 1861–1869

    Article  Google Scholar 

  71. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman J-WN (1991) Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 77: 201–205

    PubMed  Google Scholar 

  72. Wandt H, Frank M, Ehninger G et al. (1998) Safety and cost-effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91: 3601–3606

    PubMed  CAS  Google Scholar 

  73. Wernet D, Northoff H, Schnaidt M (1994) Reactivation of antibodies of donor and recipient origin to platelet antigens early after allogeneic bone marrow transplantation: a case report. Br J Haematol 88: 615–617

    Article  PubMed  CAS  Google Scholar 

  74. Wildt-Eggen Jde, Nauta S, Schrijver JG et al. (2000) Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 40: 398–403

    Article  PubMed  Google Scholar 

  75. Yankee RA, Grumet FC, Rogentine GN (1969) Platelet transfusion therapy. N Engl J Med 281: 1208–1212

    Article  PubMed  CAS  Google Scholar 

  76. Zumberg MS, del Rosario ML, Nejame CF et al. (2002) A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10000/L versus 20000/L trigger. Biol Blood Marrow Transplant 8: 569–576

    Article  PubMed  Google Scholar 

Download references

Authors
  1. H. Kroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Mueller-Eckhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Finkenweg 15, 35440, Linden, Deutschland

    Christian Mueller-Eckhardt

  2. Klinik und Poliklinik für Innere Medizin, Abteilung Transfusionsmedizin, Universitätsklinikum Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Deutschland

    Volker Kiefel

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kroll, H., Mueller-Eckhardt, C. (2004). Therapie mit Thrombozyten. In: Mueller-Eckhardt, C., Kiefel, V. (eds) Transfusionsmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10597-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10597-9_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10598-6

  • Online ISBN: 978-3-662-10597-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation